Clinical trials · New York, NY
Relapsed or Refractory Multiple Myeloma clinical trials in New York
We’re tracking 158 recruiting relapsed or refractory multiple myeloma studies with a site in or near New York — including Phase 1, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT04561206RecruitingPhase 2
Brentuximab plus nivolumab for relapsed Hodgkin lymphoma
This Phase 2 trial studies brentuximab vedotin plus nivolumab in people whose classical Hodgkin lymphoma has come back or did not respond to treatment. It aims to shrink tumors and improve control of the disease, especially when standard options like transplant are not possible.
Hackensack, New JerseyAges 18 years+ - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Hackensack, New JerseyAges 18 years+ - NCT06846281RecruitingPhase 3
Switching to remibrutinib from ocrelizumab for relapsing MS
This study tests a new oral medication called remibrutinib for people with relapsing MS who are currently on ocrelizumab. The goal is to see if switching to remibrutinib is safe and effective for controlling MS long-term.
Teaneck, New JerseyAges 40–70 - NCT06408259RecruitingPhase 3
Comparing ozanimod and fingolimod for children with MS
This study compares two oral medications, ozanimod and fingolimod, to see which one works better and is safer for children and teenagers with relapsing-remitting MS. Both drugs help reduce MS attacks and slow down the disease.
Teaneck, New JerseyAges 10–17 - NCT07325292RecruitingPhase 3
Frexalimab injection vs IV for multiple sclerosis
This study tests if a new injection (frexalimab) works as well as the IV version for people with relapsing or certain types of secondary progressive multiple sclerosis. It could offer a more convenient way to receive this treatment at home.
Teaneck, New JerseyAges 18–60 - NCT07067463RecruitingPhase 3
Testing orelabrutinib for primary progressive MS
This trial tests a daily pill called orelabrutinib to see if it can slow disability progression in people with primary progressive multiple sclerosis (PPMS). It may be an option for patients whose symptoms have been getting worse over the past two years.
Livingston, New JerseyAges 18–60 - NCT06197685Recruiting
Combining treatments to improve memory in multiple sclerosis
This trial tests a combination of two approaches to help people with MS improve memory and learning. If you have mild-to-moderate mobility issues and are not very active, you may be able to join.
East Hanover, New JerseyAges 18–70 - NCT05139017RecruitingPhase 2/Phase 3
Test drug Zilovertamab vedotin with standard care for lymphoma
This trial studies zilovertamab vedotin added to standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It may help by targeting lymphoma cells and improving how well standard treatment works after prior treatments have failed.
Morristown, New JerseyAges 18 years+ - NCT07614321RecruitingPhase 4
Silodosin for Bladder Symptoms in Women With MS
This study tests whether silodosin, a medication that relaxes bladder muscles, can help women with multiple sclerosis who have bothersome urinary symptoms. The goal is to see if it can reduce urgency, frequency, and other lower urinary tract problems.
Morristown, New JerseyAges 18 years+ - NCT07306832RecruitingPhase 1
Study of IV Pivekimab Sunirine for Children with Relapsed AML
This study tests an experimental IV drug called pivekimab sunirine for children whose acute myeloid leukemia (AML) has returned or not responded to previous treatments. The drug targets a specific marker on leukemia cells (CD123) to try to kill them.
Valhalla, New YorkAges 6 months–17 years - NCT06060873Recruiting
Using a blood test to find active germ cell tumors
This trial tests whether a blood test called miRNA-371 can detect active germ cell tumors in patients who have had surgery or are being watched. It may help guide treatment decisions without needing extra biopsies or scans.
New Brunswick, New JerseyAges 18 years+ - NCT06544265RecruitingPhase 1
SynKIR-310 for advanced B-cell lymphoma
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
New Brunswick, New JerseyAges 18 years+ - NCT04998669RecruitingPhase 2
Loncastuximab plus rituximab for relapsed follicular lymphoma
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
New Brunswick, New JerseyAges 18 years+ - NCT05730036RecruitingPhase 3
Linvoseltamab vs standard treatment for relapsed myeloma
This trial compares linvoseltamab against a standard combination (elotuzumab + pomalidomide + dexamethasone) in adults with multiple myeloma that has returned or not responded. It aims to find out whether linvoseltamab works better and is safe for people who have already had some myeloma treatments.
Stony Brook, New YorkAges 18 years+
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Relapsed or Refractory Multiple Myeloma trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting relapsed or refractory multiple myeloma studies listed above.
- Rutgers Cancer Institute of New Jersey · 3 studies
- Atlantic Health System · 2 studies
- Holy Name Medical Center · 2 studies
- New York Medical College · 2 studies
- Cooperman Barnabas Medical Center
- Hackensack University Medical Center
- John Theurer Cancer Center at Hackensack University Medical Center
- Kessler Foundation
What taking part in a relapsed or refractory multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting relapsed or refractory multiple myeloma studies in New York.
Common questions
- Are there relapsed or refractory multiple myeloma clinical trials near New York?
- Yes. We're currently tracking 158 recruiting relapsed or refractory multiple myeloma studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a relapsed or refractory multiple myeloma study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New relapsed or refractory multiple myeloma studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.